Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Celastrol attenuates osteoclast-driven bone invasion in pituitary adenomas and suppresses HSP90AA1/TRAF6/NF-κB signaling. Local targets link to admitted publications; unresolved targets remain external evidence.
The epidemiology of pituitary adenomas
10.1016/j.ecl.2020.04.002 · 2020 · External reference
Diagnosis and treatment of pituitary adenomas: a review
10.1001/jama.2016.19699 · 2017 · External reference
Diagnosis and management of pituitary adenomas: a review
10.1001/jama.2023.5444 · 2023 · External reference
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal
10.1530/erc-23-0021 · 2023 · External reference
Invasive, atypical and aggressive pituitary adenomas and carcinomas
10.1016/j.ecl.2014.10.008 · 2015 · External reference
The clinical features, recurrence risks and surgical strategies of bone invasive pituitary adenomas
10.1016/j.clineuro.2020.106455 · 2021 · External reference
Expression and clinical significance of Cathepsin K and MMPs in invasive non-functioning pituitary adenomas
2022 · External reference
PKCtheta regulates pituitary adenoma bone invasion by activating osteoclast in NF-kappaB/IL-1beta-dependent manner
10.3390/cancers15051624 · 2023 · External reference
Functions and mechanisms of tumor necrosis factor-alpha and noncoding RNAs in bone-invasive pituitary adenomas
10.1158/1078-0432.ccr-18-0472 · 2018 · External reference
The miR-19a/Cylindromatosis Axis regulates pituitary adenoma bone invasion by promoting osteoclast differentiation
10.3390/cancers16020302 · 2024 · External reference
TNF-alpha can promote membrane invasion by activating the MAPK/MMP9 signaling pathway through autocrine in bone-invasive pituitary adenoma
10.1111/cns.14749 · 2024 · External reference
LncRNA MEG8 promotes TNF-alpha expression by sponging miR-454-3p in bone-invasive pituitary adenomas
10.18632/aging.203048 · 2021 · External reference
A disintegrin and metalloproteinase 22 activates integrin beta1 through its disintegrin domain to promote the progression of pituitary adenoma
10.1093/neuonc/noad148 · 2024 · External reference
Celastrol induces apoptosis and autophagy via the AKT/mTOR signaling pathway in the pituitary ACTH-secreting adenoma cells
10.1007/s11596-022-2568-6 · 2022 · External reference
Triptolide suppresses growth and hormone secretion in murine pituitary corticotroph tumor cells via NF-kappaB signaling pathway
10.1016/j.biopha.2017.08.127 · 2017 · External reference
Triptolide inhibits pituitary adenoma cell viability, migration and invasion via ADAM12/EGFR signaling pathway
10.1016/j.lfs.2017.12.037 · 2018 · External reference
Targeted apoptosis of macrophages and osteoclasts in arthritic joints is effective against advanced inflammatory arthritis
10.1038/s41467-021-22454-z · 2021 · External reference
Celastrol attenuates bone erosion in collagen-induced arthritis mice and inhibits osteoclast differentiation and function in RANKL-induced RAW264.7
10.1016/j.intimp.2014.12.012 · 2015 · External reference
Celastrol ameliorates osteoarthritis via regulating TLR2/NF-kappaB signaling pathway
2022 · External reference
Mutations Y493G and K546D in human HSP90 disrupt binding of celastrol and reduce interaction with Cdc37
10.1002/2211-5463.12081 · 2016 · External reference
Advancements in molecular diagnosis and pharmacotherapeutic strategies for invasive pituitary adenomas
10.1002/iid3.70098 · 2024 · External reference
Celastrol as an emerging anticancer agent: current status, challenges and therapeutic strategies
10.1016/j.biopha.2023.114882 · 2023 · External reference
Celastrol, an active constituent of the TCM plant Tripterygium wilfordii Hook.F., inhibits prostate cancer bone metastasis
10.1038/pcan.2016.61 · 2017 · External reference
A comprehensive review on celastrol, triptolide and triptonide: insights on their pharmacological activity, toxicity, combination therapy, new dosage form and novel drug delivery routes
10.1016/j.biopha.2023.114705 · 2023 · External reference
Celastrol attenuates RANKL-induced Osteoclastogenesis in vitro and reduces titanium particle-induced Osteolysis and Ovariectomy-induced bone loss in vivo
2021 · External reference
Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence
2025 · External reference
Role of Cathepsin K in bone invasion of pituitary adenomas: a dual mechanism involving cell proliferation and osteoclastogenesis
10.1016/j.canlet.2025.217443 · 2025 · External reference
Early immunomodulation by magnesium ion: catalyst for superior osteogenesis
2023 · External reference
Cellular heterogeneity and inflammatory profiles in gliomas: single-cell transcriptomic insights
2025 · External reference
Toward precision oncology: leveraging bone metastatic organoid models for mechanistic, translational, and therapeutic discovery
2026 · External reference
Celastrol inhibits LL37-induced rosacea by inhibiting ca(2+)/CaMKII-mTOR-NF-kappaB activation
10.1016/j.biopha.2022.113292 · 2022 · External reference
Celastrol, an NF-kappaB inhibitor, ameliorates hypercalciuria and articular cartilage lesions in a mouse model of secondary osteoporosis
10.1016/j.jphs.2016.02.001 · 2016 · External reference
Celastrol attenuates renal injury in diabetic rats via MAPK/NF-kappaB pathway
10.1002/ptr.6314 · 2019 · External reference
Targeting HSP90 as a novel therapy for Cancer: mechanistic insights and translational relevance
10.3390/cells11182778 · 2022 · External reference
Targeting HSP90 for Cancer therapy: current Progress and emerging prospects
10.1021/acs.jmedchem.4c00966 · 2024 · External reference
Discovery of novel Celastrol derivatives as Hsp90-Cdc37 interaction disruptors with antitumor activity
10.1021/acs.jmedchem.9b01290 · 2019 · External reference
HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way
10.1186/1476-4598-9-79 · 2010 · External reference
